Confirmation of anti‐tumor activity and lack of toxicity for the drug combination in both immune‐suppressed and immune‐competent recipients also makes unlikely that AZD8186 (p110β/δ inhibitor) exerts its effects by targeting p110δ in the immune cell compartment. This evidence concerns the gene PIK3CD and neoplasm.